Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Abbott; Bio-Rad Laboratories; Prometheus Laboratories; GeneGo, Sigma-Aldrich; Fluidigm

NEW YORK (GenomeWeb News) – Abbott received CE Marking in the European Union for its RealTime mS9 Colorectal cancer test, a non-invasive DNA assay that detects the methylated form of Septin 9. The assay, which runs on Abbott's m2000 PCR-based molecular diagnostic system, can be used by physicians to determine if a patient should be referred for colonoscopy. The test is not available for sale in the US, the firm noted.


Bio-Rad Laboratories this week completed its acquisition of Germany-based Biotest for €45 million ($64.5 million). The acquisition will expand bio-Rad's presence in the immunohematology testing field.


Prometheus Laboratories, which develops pharmaceuticals and personalized diagnostic products, said this week that it has executed a $260 million senior secured credit facility, consisting of a $210 million term loan and a $50 million revolving credit line.


GeneGo has included access to Sigma-Aldrich life science and chemistry products in its MetaCore 6.0, MetaDrug, and Eureka products. GeneGo said that customers could now retrieve comprehensive information on drugs and compounds and make one-click purchases from one centralized location.


The US Department of Agriculture has purchased and is using Fluidigm's microfluidic-based EP1 System to help develop and validate focused 96- and 384-SNP panels for testing dairy and beef cattle, the firm said this week.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more